Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Down 29.3% in December

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 8,200,000 shares, a decrease of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily trading volume, of 705,500 shares, the short-interest ratio is currently 11.6 days.

Hedge Funds Weigh In On Atossa Therapeutics

Several hedge funds have recently bought and sold shares of ATOS. Bank of New York Mellon Corp grew its holdings in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after buying an additional 164,540 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics in the 2nd quarter worth about $161,000. Barclays PLC grew its stake in Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after acquiring an additional 123,683 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Atossa Therapeutics by 177.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock valued at $227,000 after acquiring an additional 95,643 shares in the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ATOS has been the topic of a number of analyst reports. Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th.

Atossa Therapeutics Price Performance

Shares of ATOS stock traded down $0.08 during midday trading on Friday, reaching $0.98. 995,209 shares of the company traded hands, compared to its average volume of 1,061,169. The firm’s 50 day simple moving average is $1.27 and its two-hundred day simple moving average is $1.31. The firm has a market cap of $123.42 million, a PE ratio of -4.46 and a beta of 1.21. Atossa Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.31.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.